EVOLVE-106 / EvolveImmune Therap - LARVOL DELTA

EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) - "EvolveImmune Therapeutics...announced that new preclinical and translational data highlighting EV-104 and EV-106, two programs utilizing EVOLVE, the company’s proprietary costimulatory T cell engager platform were presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....EV-104 showed robust single-agent anti-tumor activity in patient-derived tumor models of bladder and lung cancer and demonstrated promising activity in combination with anti-PD1 therapy in pre-clinical models with patient-derived tumors, providing rationale for combination treatment approaches with checkpoint inhibitors....New findings demonstrated robust single-agent anti-tumor activity by EV-106 lead molecules in three different preclinical breast cancer cell assay systems that was superior to B7-H4-targeted CD3 T cell engagers being advanced by competitors which do not employ integrated CD2 costimulation."

Preclinical • Bladder Cancer • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

EVOLVE-106, a T cell engager with integrated CD2 costimulation targeting B7-H4, is a precision therapy for estrogen and Her2 receptor low breast cancers (SITC 2023) - "We found that HR+ breast cancer cell lines treated with the selective estrogen-degrader fulvestrant, displayed increased B7-H4 levels and combination treatment of EVOLVE-106 with fulvestrant increases EC50 of tumor killing by 5–8 fold. Conclusions These data support the potential positioning of EVOLVE-106 as a first-in-category immunotherapeutic approach for patients with Her2 receptor low breast cancers, and both estrogen receptor positive and negative tumors, including TNBC."

IO biomarker • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD2 • ER • HER-2 • VTCN1

EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) - "EvolveImmune Therapeutics...announced that new preclinical and translational data highlighting EVOLVE, the company’s novel costimulatory T cell engager platform, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 1-5, 2023, in San Diego, California....In two poster presentations, EvolveImmune will highlight how the differentiated aspects of the EVOLVE platform are being applied to two solid tumor programs, EV-104 and EV-106."

Preclinical • Breast Cancer • Oncology • Solid Tumor